Edition:
United States

GlaxoSmithKline PLC (GSK.N)

GSK.N on New York Stock Exchange

40.19USD
16 Aug 2019
Change (% chg)

$0.23 (+0.58%)
Prev Close
$39.96
Open
$40.21
Day's High
$40.38
Day's Low
$40.15
Volume
310,144
Avg. Vol
532,590
52-wk High
$42.46
52-wk Low
$36.42

About

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company... (more)

Overall

Beta: 1.01
Market Cap(Mil.): $98,615.21
Shares Outstanding(Mil.): 2,459.32
Dividend: 0.50
Yield (%): 6.13

Financials

  GSK.N Industry Sector
P/E (TTM): 39.40 29.89 32.67
EPS (TTM): 1.03 -- --
ROI: 7.58 14.89 14.48
ROE: 278.84 16.01 15.78

IN BRIEF: GSK to face first Zofran birth defects trial in January

A federal judge overseeing hundreds lawsuits by women who claim the anti-nausea drug Zofran causes birth defects and that GlaxoSmithKline PLC failed to warn of its risks on Wednesday said the first trial nationally would take place in January.

Aug 14 2019

AstraZeneca scores win in race to treat ovarian cancer

FRANKFURT AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer.

Aug 14 2019

AstraZeneca scores win in race to treat ovarian cancer

FRANKFURT, Aug 14 AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer.

Aug 14 2019

GSK ends development of Ebola vaccine, hands work to U.S. institute

LONDON British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

Aug 06 2019

UPDATE 1-GSK ends development of Ebola vaccine, hands work to U.S. institute

LONDON, Aug 6 British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

Aug 06 2019

GSK hands work on potential Ebola vaccines to U.S. institute

LONDON, Aug 6 British drugmaker GlaxoSmithKline is handing over all its development work on three potential vaccines against the deadly Ebola and Marburg viruses despite an ongoing Ebola outbreak in Democratic Republic of Congo.

Aug 06 2019

GSK raises 2019 earnings expectations after standout quarter for Shingrix

GlaxoSmithKline beat second quarter profit expectations with the help of strong demand for its shingles vaccine, prompting the British drugmaker to forecast a smaller fall in profit this year than originally anticipated.

Jul 24 2019

WRAPUP 1-GSK raises 2019 earnings expectations after standout quarter for Shingrix

July 24 GlaxoSmithKline beat second quarter profit expectations with the help of strong demand for its shingles vaccine, prompting the British drugmaker to forecast a smaller fall in profit this year than originally anticipated.

Jul 24 2019

REFILE-UPDATE 1-GSK predicts smaller fall in 2019 profit after standout quarter for Shingrix

July 24 GlaxoSmithKline Plc on Wednesday forecast a smaller than previously estimated fall in full-year profit after the British drugmaker beat profit consensus for the second quarter due to demand for its fast-growing Shingles vaccine.

Jul 24 2019

GSK forecasts smaller hit to FY profit after Q2 beat

July 24 GlaxoSmithKline Plc on Wednesday forecast a smaller-than estimated fall in full-year profit after the British drugmaker beat profit consensus for the second quarter due to demand for its fast-growing Shingles vaccine.

Jul 24 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates